Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Replimune Group, Inc. (REPL) AI Forecast

Our AI ranks Replimune Group, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$REPL Bullish Signal Full forecast available
Sign Up Free

Replimune Group, Inc. (REPL) Stock Forecast Sept. 21, 2026

Replimune Group, Inc. (REPL) AI Stock Price Forecast & Investment Analysis

Replimune Group, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Replimune Group, Inc. (REPL) - Comprehensive Stock Analysis & Investment Research

Deep dive into Replimune Group, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Replimune Group, Inc. Investment Summary

When evaluating whether Replimune Group, Inc. (REPL) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Replimune Group, Inc. (REPL) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $1 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Replimune Group, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Replimune Group, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Replimune Group, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Replimune Group, Inc.

Sign Up Free
Corporate Identity

Replimune Group, Inc. (Stock Symbol: REPL) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Replimune Group, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Replimune Group, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Replimune Group, Inc....

Unlock Full Company Profile

Get complete details about Replimune Group, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Replimune Group, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Replimune Group, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Replimune Group, Inc....

Unlock Financial Analysis

Get complete financial metrics for Replimune Group, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Replimune Group, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Replimune Group, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Replimune Group, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-281 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 5.23 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Replimune Group, Inc. (REPL) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Replimune Group, Inc. stock analysis.

Deep dive into Replimune Group, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Replimune Group, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Replimune Group, Inc.:

P/B Ratio 11.66x
Market Cap $1.23B
EPS $-3.15
Book Value/Share $1.12
FCF/Share $-2.98
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Replimune Group, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Replimune Group, Inc.: An ROE of -281.1% indicates room for improvement in shareholder value creation.

ROE -281.1%
ROA -117.7%
ROIC -139.1%
Tax Rate 0.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Replimune Group, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Replimune Group, Inc.: A current ratio of 5.23 indicates strong liquidity.

Current Ratio 5.23x
D/E Ratio 1.39x
Financial Leverage 2.39x
Interest Coverage -26.4x
Working Capital $162M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Replimune Group, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Replimune Group, Inc.: Free cash flow of $-281M indicates cash challenges that need attention.

Operating Cash Flow -$279M
Free Cash Flow -$281M
Capital Spending -$1M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Replimune Group, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Replimune Group, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Replimune Group, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Replimune Group, Inc.:

Income Statement
Operating Income -$297M
Net Income -$297M
R&D Expense $213M
Balance Sheet Highlights (USD millions)
Total Current Assets $201M (79.6% of assets)
Cash & Short-term Investments $185M (73.4% of assets)
Total Liabilities $147M (58.2% of assets)
Short-term Debt $34M (13.5% of assets)
Dividend & Shareholder Information
Shares Outstanding 94M

Latest Replimune Group, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Replimune Group, Inc. (REPL) stock price and investment outlook.

📰 Loading...

Where REPL sits on the market map

Explore the map →

Replimune Group, Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Replimune Group, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
REPL ██% $1.23B x 11.7x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Replimune Group, Inc. Stock Forecast

How accurate are Replimune Group, Inc. stock predictions?

A per-ticker accuracy statistic for REPL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Replimune Group, Inc. stock price forecasts?

Our analysis considers Replimune Group, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Replimune Group, Inc. a good investment in 2026?

Based on our AI analysis, Replimune Group, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Replimune Group, Inc. forecasts updated?

Replimune Group, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Replimune Group, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...